 CAMBRIDGE, Mass., Nov. 09, 2021 GLOBE NEWSWIRE -- Vor Biopharma Nasdaq: VOR, a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell therapy platform at the Society for Immunotherapy of Cancer SITC 36th Annual Meeting, taking place in Washington D.C., from November 10-14, 2021. 